Estriol succinate - Synthetic Biologics

Drug Profile

Estriol succinate - Synthetic Biologics

Alternative Names: Estriol - Synthetic Biologics; Oestriol - Synthetic Biologics; Trimesta

Latest Information Update: 08 Feb 2016

Price : $50

At a glance

  • Originator National Institutes of Health (USA); University of California at Los Angeles
  • Developer Synthetic Biologics
  • Class Estrenes; Hormonal replacements
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Multiple sclerosis

Most Recent Events

  • 08 Feb 2016 Discontinued - Phase-II for Multiple sclerosis (Adjunctive treatment) in USA (PO)
  • 02 Feb 2016 Synthetic Biologics terminates its licence for estriol succinate worldwide
  • 02 Feb 2016 Final efficacy data from a phase II trial in Multiple sclerosis released by Synthetic Biologics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top